Advancing Core Product ICVAX® for HIV & Immunotherapy Pipeline for Cancers
HONG KONG SAR – Media OutReach Newswire – 13 November 2026 – Yicura BioMed ("Yicura"), a clinical-stage immunotherapy company based in the Hong Kong Science Park developing medicines for infectious diseases, cancers, and inflammatory diseases, is pleased to announce today the first closing of its Series B financing led by Gobi Partners, with participation from a number of strategic investors from Wuxi and institutional investors from Hong Kong. Their participation reflects shared confidence in Yicura's clinical development path. Proceeds will be deployed to advance the core product ICVAX® for HIV and to accelerate the development of the immunotherapy pipeline for cancers across the vaccine and antibody programmes.
ICVAX® has completed a randomised, placebo-controlled NMPA-approved Phase I clinical trial in people living with HIV on antiretroviral therapy, with favourable safety and immunogenicity performance. The program is advancing to Phase II clinical trial for efficacy evaluation for a more durable immune control of HIV and the target path to functional cure.
"This funding round marks an important step in Yicura's growth as we move ICVAX® from early clinical validation towards efficacy studies," Dr. Xia JIN, Co-Founder and CEO of Yicura, said. "We are encouraged by the Phase I data of ICVAX® and the potential of our PD-1-enhanced DNA vaccine and anti-∆42PD1 antibody platforms to address serious unmet needs in infectious diseases, cancers and inflammation. We are grateful for Gobi Partners' partnership and the investors' confidence in our science, our team and our mission to develop immunotherapies that can meaningfully change the standard of care for patients."
"Yicura is building a distinctive suite of immunotherapies from Hong Kong, with a clear clinical lead in ICVAX® and platform technologies that can extend well beyond a single indication to precision therapies for cancers." Mr. Fred LI, Managing Director and Head of University Ventures of Gobi Partners, shared, "We are pleased to lead this Series B financing and to support Dr. JIN and the Yicura team as they advance the promising HIV therapeutic vaccine and continue to translate their brilliant technologies into medicines for patients in need."
Hashtag: #醫克生物 #Yicura
http://www.yicura.hk
https://www.linkedin.com/company/yicura
The issuer is solely responsible for the content of this announcement.
About Yicura BioMed (formerly known as Immuno Cure)
Yicura BioMed ("Yicura") is a clinical-stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammations, and infectious diseases based on its patented PD-1-enhanced DNA vaccine and anti-Δ42PD1 antibody platforms.
To learn more about Yicura, please visit: http://www.yicura.hk
About Gobi Partners
Founded in 2002, Gobi Partners is a leading pan-Asian investment firm specialising in bespoke capital solutions for family offices, sovereign wealth funds, financial institutions and corporate investors. Headquartered in Hong Kong and Kuala Lumpur, Gobi manages US$2 billion across 30+ investment vehicles, investing in early to growth-stage companies with the potential for generational and global impact.
The firm's team of over 90 investment professionals operates from 18 locations, curating a diversified portfolio of more than 400 companies, with 76 exits achieved to date. Gobi is recognised for its long-term, values-aligned approach, building ecosystems at the intersection of technology, sustainability, and inclusion. From pioneering TaqwaTech for two billion Muslims, to advancing the circular economy, to promoting gender-diverse leadership, Gobi backs the trends that are reshaping societies.
Gobi's edge lies in identifying structural and demographic shifts, forging partnerships with universities and institutions of higher education; bridging world-class research with private capital and bringing deep technology breakthroughs to commercialisation.
Official Website: https://gobi.vc
Official Linkedin: https://www.linkedin.com/company/gobipartners/
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
Built by AI Rudder, CALL-E asks the user before every call and reports back with proof of what was agreed.
SAN FRANCISCO, US – Media OutReach Newswire – 13 November 2026 – AI Rudder, the Singapore-headquartered company behind more than 80 billion AI calls, has launched CALL-E, which lets AI agents make real phone calls on their users' behalf. CALL-E works inside ChatGPT, in personal AI agents such as Muse, OpenClaw and Hermes Agent, and in AI coding tools such as Claude Code, Codex and Cursor.
Personal AI agents are growing fast. Meta's Muse passed five million US downloads in its first three weeks, and Grok Bot, from Elon Musk's SpaceX, reached 400,000 weekly users in its first month. Both are piloting phone calls, and users now try to hand their AI agent the calls they used to make themselves: moving a dinner booking, chasing the dry cleaner.
CALL-E is built for those calls. A personal AI agent hands it the errand, and CALL-E makes the call and reports back with proof.
"The smartest AI model in the world can still fail a phone call. All it takes is one 'mm-hmm'," said Teng Ren, CEO of AI Rudder.
"Say your AI agent calls a restaurant to move your booking to a specific time. The restaurant host says 'mm-hmm' to agree, and your agent stops mid-sentence, as if she'd asked a question. Then she says, 'Tuesday at... let me check,' and your agent cuts in with 'Great, Tuesday it is,' to a time she did not give. These behaviours are unnatural to a human, so she knows she's talking to AI and hangs up.
"An AI agent earns the right to speak for us when it reads every 'yes', every pause and every interruption the way a person on the phone would, and answers the way that person would."
A call can't be unsent. CALL-E builds an approval step into the product: each call goes ahead only after the user approves that exact plan, so a call nobody approved never rings.
Phone calls are messier than chat. People pause halfway through an order number, talk over the agent, or cut in mid-sentence. AI Rudder's engineers handle this in the code around the AI model, which decides what the model hears and what it remembers saying.
On the TurnBench Interruption leaderboard, Helm Swift, the AI Rudder model that tells CALL-E when a caller is cutting in, has the joint-lowest false-positive rate of any qualifying model, so it rarely stops talking just because a caller says "yeah" (TurnBench, October 2026).
An agent can report "Booked for 7pm" and still have misheard the time. So after each call, CALL-E reports what was agreed, how confident it is that it met the goal, and the exact lines from the call that back it up, so the user can check it.
By default, a CALL-E call introduces itself as CALL-E, a voice agent. The user can change what it says, and a pre-check stops a call from posing as the FBI or 911.
Regulators are moving the same way. In its 2024 Declaratory Ruling (FCC 24-17), the FCC clarified that AI-generated voices fall within the definition of artificial or prerecorded voices under the Telephone Consumer Protection Act, making such calls subject to applicable regulatory requirements, including consent and caller identification obligations. Separately, Article 50 of the EU AI Act requires that people be told they are talking to an AI.
An agent that calls for you carries your phone number and the details of your errand, so the line it uses has to keep both safe. CALL-E runs on the same technology as AI Rudder's enterprise solutions, which are built to meet SOC 2 Type 2 and ISO 27001, alongside GDPR and PDPA requirements. Every call keeps a record from plan to result, with the approval and the evidence attached, so a disputed call can be traced.
CALL-E is available at https://www.heycall-e.com/, where new users start with 100 free credits.
Hashtag: #AIRudder
https://www.linkedin.com/company/airudder/
CALL-E on X: https://x.com/heycalle
The issuer is solely responsible for the content of this announcement.
About CALL-E
CALL-E lets an AI agent make real phone calls for the person it works for: it plans the call, waits for the user's approval, makes the call and reports back with proof of what was said. CALL-E is built by Singapore-headquartered AI Rudder, which is backed by investors including Tiger Global and Peak XV Partners.
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
Illustration: a personal AI agent makes calls for its user with CALL-E. (Image: AI Rudder)
